EXAS - Exact Sciences Corporation
103.40 0.00 (0.00%)
After hours: 5:07PM EDT
| Previous Close | 105.44 |
| Open | 105.38 |
| Bid | 103.50 x 3200 |
| Ask | 103.50 x 800 |
| Day's Range | 103.05 - 106.31 |
| 52 Week Range | 53.06 - 123.99 |
| Volume | 1,057,141 |
| Avg. Volume | 1,544,860 |
| Market Cap | 13.389B |
| Beta (3Y Monthly) | 2.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.76 |
| Earnings Date | Oct 28, 2019 - Nov 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 133.44 |
- Zacks
Stock Investors: Do You Need a Late Cycle Plan?
The financial media keeps talking about the economy being in the late cycle but that doesn't mean you can't be buying stocks.
- PR Newswire
Exact Sciences Named One of the 2019 Best Workplaces for Women by Great Place to Work® and FORTUNE
MADISON, Wis., Sept. 19, 2019 /PRNewswire/ -- Exact Sciences is a member of the 2019 Best Workplaces for Women list, an honor given by Great Place to Work® and FORTUNE to employers providing supportive, inclusive workplaces. To determine the Best Workplaces for Women, Great Place to Work® analyzed anonymous survey feedback representing more than 4.6 million employees at Great Place to Work-CertifiedTM organizations. "Our work to deliver life-changing innovations in earlier cancer detection relies on a heavily engaged team," said Sarah Condella, senior vice president of Human Resources at Exact Sciences.
- PR Newswire
Cologuard® Helps More People Get Screened In A Cost-Effective Way
MADISON, Wis., Sept. 10, 2019 /PRNewswire/ -- (EXAS) -- Exact Sciences announced today that nearly 3 million people have been screened for colorectal cancer with Cologuard since FDA approval with half of those tested being previously unscreened. Not only is Cologuard increasing the number of screened Americans, peer reviewed data shows that Cologuard is a cost-effective alternative for people at average risk for colorectal cancer (CRC). Data conclusively shows that screening reduces colorectal cancer incidence and mortality. However, for over a decade, 1 out of every 3 Americans eligible for screening under current guidelines has gone unscreened, leading to colorectal cancer incidence and mortality rates that are higher than they should be. Cologuard is an innovative, stool-based DNA test that was created to help improve the nation's stagnant screening rate.
- Simply Wall St.
Is Exact Sciences (NASDAQ:EXAS) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- PR Newswire
Exact Sciences to participate in September investor conference
MADISON, Wis., Aug. 30, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conference and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer.
- Zacks
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health
- Zacks
3 Cancer Treatment Stocks to Enrich Your Portfolio
Investments in cancer therapies are expected to rise almost $250 billion by 2023, from $150 billion in 2018. Thus, companies that are coming up with innovative methods to cure this malaise are great investment choices.
- American City Business Journals
Third in wave of Bay Area biotech IPOs eyes $100M windfall after 26 years in business
Seeking to win where no one has succeeded before in cancer and build out its own manufacturing, this Mountain View company takes its place in a growing line of Bay Area biotech IPOs.
- Motley Fool
A Breach of Trust? Here's Why the FDA's Taking Aim at Novartis' AveXis
What Novartis' misstep means to investors, plus how Exact Sciences is trying to lock up the genetic testing market.
- Investopedia
10 Stocks That Can Profit as Global Turmoil Escalates
The 22% average annual gain of 'idiosyncratic growth' stocks is far superior to the market, says BofA.
- Motley Fool
Genomic Health's Second Quarter Was So Great It Got the Company Acquired
Exact Sciences takes out the cancer-test maker for $2.8 billion.
- Motley Fool
Here's Why Genetic Testing Stocks Rose as Much as 25.4% in July
It was a great month to be a genetic testing company.
- PR Newswire
GENOMIC HEALTH INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Genomic Health, Inc. - GHDX
NEW ORLEANS , Aug. 2, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale ...
- PR Newswire
Exact Sciences to participate in August investor conference
MADISON, Wis., Aug. 2, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conference and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer.
- GuruFocus.com
Acquisition Boosts Exact Sciences' Role in Cancer Diagnostics
Purchase of Genomic Health expands testing capabilities and R&D; Continue reading...
- GuruFocus.com
Exact Sciences Corp (EXAS) CFO Jeffrey Thomas Elliott Sold $1 million of Shares
CFO of Exact Sciences Corp (30-Year Financial, Insider Trades) Jeffrey Thomas Elliott (insider trades) sold 9,845 shares of EXAS on 07/30/2019 at an average price of $105.6 a share. Continue reading...
- American City Business Journals
Pioneering cancer test maker's execs could grab millions in $3 billion buyout
Kim Popovits helped build Genomic Health into a leading molecular diagnostics company over a 17-year career. She could leave the Redwood City company with millions of dollars.
- InvestorPlace
7 Strong Buy Stocks the Street Loves
[Editor's note: "7 Strong Buy Stocks the Street Loves" was previously published in April 2019. It has since been updated to include the most relevant information available.]Which top stocks are Wall Street analysts the most bullish on? I mean stocks with a strong "buy" analyst consensus. These are the stocks that make the most compelling investing opportunities and are definitely worth keeping a close eye on.Using TipRanks powerful stock screener, I set out to pinpoint seven stocks that command the support of the Street. You can customize the screener settings to match your investment strategy. In this case, I selected filters for stocks of all market cap size with a "buy" consensus from analysts and best-performing analysts alike. These are the top analysts with the highest success rate and average return.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHere I specifically select stocks with big upside potential from the current share price. This is based on the upside potential from the current share price to the average analyst price target. * The 10 Best Stocks to Invest in for August Now let's delve into these seven top stocks to buy now: Strong Buy Stocks: Exact Sciences (EXAS)Earlier this year, Exact Sciences Corporation (NASDAQ:EXAS) has just received five back-to-back buy ratings from the Street. These "buys" flooded in following stellar Q4 earnings results. EXAS delivered a solid Q4 revenue beat and raised its 2019 revenue guidance to $710 million-$730 million, above its prior $700 million estimate.Plus the future looks bright for sales of its Cologuard DNA test for colon cancer."EXAS is one of our top picks for 2019, and we reiterate our "buy" rating and our $100 PT," said five-star Canaccord Genuity analyst Mark Massaro. "Exact continues to execute at a high level and isn't afraid to make big investments to hit its ambitious goal of achieving $6 billion of revenue for Cologuard over time."That would give the company over 40% market share for its revolutionary screening product, first launched back in 2014.According to Massaro, even the new revenue guidance is beatable, writing "we see a path to upside to our raised estimates." A similar message comes from Baird's Catherine Ramsey. She writes: "We continue to see the potential for upside… and EXAS remains one of our top ideas."The average analyst price target right now stands at $128.33. Bear in mind shares have surged 87% year-to-date. Want to learn more about Exact Sciences? Get the free EXAS Stock Research Report. OpenText (OTEX)Canadian cloud computing stock Open Text Corp (NASDAQ:OTEX) develops and sells enterprise information management (EIM) software. Essentially, this helps organizations safely manage and share business information.Since the company's inception in 1991, OpenText has deployed around $6 billion capital on acquisitions. Using these acquisitions, OTEX can cement its position as a leader in the EIM space."Our strategy is total growth," said CEO Mark Barrenechea said, "where M&A will continue to be our largest growth driver, augmented with organic growth." So far this strategy appears to be paying off. * The 10 Best Stocks to Invest in for August "We believe OpenText is likely to continue to create shareholder value through its acquisition strategy," RBC analyst Paul Treiber said following the encouraging Q2 numbers,Analysts have a $46.75 average price target on the shares -- over 10% above the current share price. Get the OTEX Stock Research Report. Moderna (MRNA)Moderna (NASDAQ:MRNA) is a pioneer in a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching. No less than eight analysts have published recent buy ratings on the stock.Earlier this year, the company reported positive results from an ongoing phase Ib trial. This is for mRNA-1653, an mRNA-based vaccine for the treatment of human metapneumovirus (HMPV) and parainfluenza virus (PIV3)."The interim phase I data announced today support our outlook for this experimental product and support advancing studies in the pediatric population" said Oppenheimer's Leah R Cann.The mRNA-1653 program is one of Moderna's 21 most current and importantly, one of its 13 focus programs.She points out that currently there are no approved vaccines to prevent hMPV or PIV3 infections, and estimates that worldwide mRNA-1653 sales could reach $1.44 billion by 2030. That's with a predicted launch date of 2024. Get the MRNA Stock Research Report. Nexstar Media (NXST)Following its completion of the Media General acquisition, Nexstar Media Group (NASDAQ:NXST) owns 171 television stations. As the largest TV station operator in the U.S. reaching nearly 39% of households, Nexstar Media Group is a stock worth watching.Analysts certainly seem to think so. Nexstar has received many buy calls in recent months from the Street. Most notably, Evercore ISI's David Joyce upgraded NXST from "hold" to "buy" back in December.Crucially, the company recently acquired many stations. It has agreed to a $6.4 billion deal to buy Tribune's ABC, CBS, FOX, and NBC stations. Tribune shareholders recently approved the deal. What's more, to help avoid any anti-trust issues, Nexstar has announced that it would sell 14 stations. * The 10 Best Stocks to Invest in for August "We assign Nexstar an Outperform rating and a $112 price target. We believe that the Tribune acquisition should create significant value for shareholders," top RBC Capital analyst Leo Kulp tells investors.He ramped up his price target from $96 to $112, adding, "We see limited risk around regulatory approvals…We expect the FCF yield to moderate as the company completes the milestones to closing the deal and de-levers post-closing." Get the NXST Stock Research Report. Boyd Gaming (BYD)Shares in Boyd Gaming Corp (NYSE:BYD) have jumped 34% in 2019 . That's partially thanks to a pretty exceptional Q4 earnings report for the Paradise, Nevada-based casino company."BYD's 4Q18 operating results were nothing short of sensational," said five-star Stifel Nicolaus analyst Steven Wieczynski. "BYD's strong 4Q18 results (were) an exclamation point on a strong 2018, with guidance above expectations serving as the cherry on top."With widespread growth throughout the business, BYD EBITDAR came in at $208.6mm, easily surpassing the estimated $197.1 million. Meanwhile 2019 EBITDAR guidance was established at a healthy $885 million-910 million, the midpoint of which was above Consensus forecasts ahead of the print ($888 million)."Post the strong 4Q18 results and with, we believe BYD is well positioned to continue to show healthy and steady same-store growth, while continuing to integrate its accretive acquisitions from the 2H18," said Deutsche Bank's Carlo Santarelli.That's with a "very compelling" current valuation to boot. With a " buy" analyst consensus, BYD boasts fa $35.60 average price target (25% upside potential). Get the BYD Stock Research Report. LivePerson (LPSN)As the name suggests, LivePerson (NASDAQ:LPSN) provides online real-time assistance and expert advice. The cloud-based chat company is near its all-time highs after its CEO in May said that it expects to end the year with an annual revenue run rate of around 20%. Shares are now up 73% year-to-date.Going forward, analysts are firmly bullish about LivePerson's outlook. Many analysts have published "buy" ratings on the stock this year, including (five-star Oppenheimer analyst Koji Ikeda. * The 10 Best Stocks to Invest in for August "We believe LivePerson is well positioned to take share in a large B2C messaging opportunity that is disrupting the contact center" writes Ikeda. "Organizations around the world are under pressure to rethink and retool legacy technologies with next-generation customer engagement applications, like LivePerson, to better engage, retain, and generate revenue from the end-consumer" the analyst explains.He believes that over time, good execution in quarterly results and improving business fundamentals should narrow the valuation gap between LPSN and the SaaS Industry average. That makes it a great strong buy stock. Get the LPSN Stock Research Report. Cubic Corp (CUB)Despite Brexit concerns and increasing volatility, growth remains par for the course for Irish defense contractor Cubic Corp (NYSE:CUB).The company has three key business divisions. For investors, it is the company's flagship Cubic Transportation Systems unit that is worth keeping an eye on. According to the company, this is the division responsible for "automated fare payment, traffic management and enforcement solutions."Indeed, transport systems revenue was up 24% year over year, according to CUB's Q1 earnings report. Consequently, Citigroup's Jonathan Raviv cited recent wins- especially in transport- as behind his bullish take on the stock.Meanwhile, Drexel Hamilton's David Williams wrote: "We remain positive on CUB and expect further acquisitions to supplement top and bottom-line growth, which is likely to drive short term upside to expectations, and provide a strong long-term growth trajectory."As such, the analyst reiterates his "buy" rating and $85 price target (38% upside potential) on this strong buy stock. Six analysts give the stock a buy rating, while their average price target works out at $76.40. Get the CUB Stock Research Report.TipRanks.com offers exclusive insights for investors by focusing on the moves of experts: Analysts, Insiders, Bloggers, Hedge Fund Managers and more. See what the experts are saying about your stocks now at TipRanks.com. As of this writing, Harriet Lefton did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Reasons Kraft Heinz Stock Is a Contrarian Buy * 5 Housing Stocks to Buy for Renewed Homebuilder Confidence * 7 of the Best ETFs to Buy for a Rock-Solid Portfolio The post 7 Strong Buy Stocks the Street Loves appeared first on InvestorPlace.
- TheStreet.com
Short Seller Left Goes Long on Invitae With $100 Target
Invitae was trading up 1.4% to $27.56 after the Citron analyst published a note and placed a $100 price target on the stock. The company has an "indestructible moat" around genetic testing, Left wrote. Invitae "has now realized that genetic testing will become a cornerstone of healthcare and has taken a page out of the [Exact Science ] playbook by going direct to consumer with a clinical grade product that requires a clinician," Left said.
- Simply Wall St.
A Look At The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)
In this article we are going to estimate the intrinsic value of Exact Sciences Corporation (NASDAQ:EXAS) by taking the...
Motley FoolExact Sciences Corp (EXAS) Q2 2019 Earnings Call Transcript
EXAS earnings call for the period ending June 30, 2019.
- Motley Fool
Here's Why Exact Sciences Stock Snapped Right Back Into Place
At first glance, an acquisition announcement looked like the wrong deal.
- TheStreet.com
Exact Sciences Is Poised to Test New Highs on the Charts
For his "Executive Decision" segment of Mad Money Monday night, Jim Cramer spoke with Kevin Conroy, chairman and CEO of Exact Sciences Corp. , a stock that's up 80% for the year. In addition to reporting earnings Monday, EXAS announced a deal to acquire Genomic Health for $2.8 billion. Conroy said he can't wait to see what the combined companies can accomplish.
- PR Newswire
SHAREHOLDER ALERT: WeissLaw LLP Investigates Genomic Health, Inc.
NEW YORK , July 29, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Genomic Health, Inc. ("Genomic ...
